Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Reata Pharmaceuticals identifies new nitric oxide production inhibitors

Feb. 15, 2021

Tukysa approved in E.U. for HER2-positive locally advanced or metastatic breast cancer

Feb. 12, 2021

Bristol Myers Squibb synthesizes IRAK-4 inhibitors

Feb. 12, 2021

New cancer anorexia therapeutic target identified

Feb. 12, 2021

Dependencies join mutations in precision medicine search

Feb. 11, 2021

Artios initiates phase I/IIa trial of ATR inhibitor ART-0380 in advanced or metastatic solid tumors

Feb. 11, 2021

New phase III study evaluates AZD-9833 with palbociclib in ER-positive HER2-negative breast cancer

Feb. 11, 2021

French researchers describe PD-1/PD-L1 interaction inhibitors

Feb. 11, 2021

Kinnate Biopharma synthesizes new CDK inhibitors

Feb. 11, 2021

Korean investigators disclose tubulin polymerization inhibitors

Feb. 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...